Venturi Cardiology and Caristo Diagnostics Introduce AI-Enabled Heart Disease Diagnosis and Prevention Technology in North West England
OXFORD, England, Sept. 18, 2024 /PRNewswire/ — Venturi Cardiology, a leading, state of the art cardiology clinic in North West England offering rapid access to clinical consultations and advanced diagnostics, has partnered with Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, to offer Caristo’s AI-enabled CaRi-Heart® technology to patients in its growing practice. Venturi Cardiology is part of DHC Group, a portfolio of healthcare companies that supply specialist outpatient pathways and diagnostic imaging services.
CaRi-Heart technology applies advanced AI algorithms to routine coronary computed tomography angiography (CCTA) scans to visualise and quantify coronary inflammation, the otherwise invisible disease mechanism responsible for many fatal heart attacks. Venturi Cardiology are initially offering an Incentivised Test package for patients requesting CaRi-Heart analysis as part of their CCTA (Coronary Computed Tomography Angiography) scan. Further details can be found on their website: www.venturicardiology.com/cari-heart-analysis.
“At Venturi, our approach to cardiac care is preventative and personalised for each patient. We are excited to offer the CaRi-Heart AI technology, which reveals an individual’s risk of heart attack over the next 8-10 years. This groundbreaking technology can revolutionise early detection and prevention of coronary artery disease,” said Dr Scott Murray, Consultant Cardiologist and Medical Director at Venturi Cardiology.
“Coronary artery disease is the world’s No. 1 killer, but its impact could be dramatically reduced if physicians were able to spot coronary inflammation before a patient suffers from a fatal or non-fatal cardiac event. We are delighted to partner with Venturi Cardiology and DHC Group to bring this life-saving technology to their patients. This partnership will allow increased patient access to the innovative CaRi-Heart technology and can transform the management and treatment of coronary artery disease,” said Frank Cheng, CEO, Caristo Diagnostics.
As confirmed in a recent peer-reviewed study in The Lancet, CaRi-Heart’s unique biomarker, the FAI-Score™, detects invisible coronary inflammation and assesses an individual’s risk of a fatal cardiac event. This is potentially lifesaving for patients who, despite a negative CCTA result, remain at high risk for cardiovascular events. Addressing this residual risk is a significant unmet need in cardiac care.The landmark Lancet study conducted by researchers at the University of Oxford and other UK clinical institutions analysed results from 40,000 patients’ CCTAs, finding that:
- About 80% of patients did not have obstructive coronary artery disease at the time of imaging, but twice as many fatal and non-fatal cardiac events occurred in that group
- Coronary inflammation, as measured by Caristo’s CaRi-Heart FAI-Score, predicted fatal and non-fatal cardiac events (including heart attack and new heart failure), independently from traditional risk factors, routine clinical CCTA interpretation, calcium scoring and plaque quantification, at least 10 years in advance
- The CaRi-Heart Risk Score outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management in 45% of the patients.
CaRi-Heart technology is currently in clinical use across the UK, European Union, and Australia.
